These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 24076604)

  • 21. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
    García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
    Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interaction of histone modification related H3F3B and NSD2 genes increases the susceptibility to schizophrenia in a Chinese population.
    Liu W; Fang Y; Shi Y; Cheng Y; Sun C; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109918. PubMed ID: 32169559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.
    Oyer JA; Huang X; Zheng Y; Shim J; Ezponda T; Carpenter Z; Allegretta M; Okot-Kotber CI; Patel JP; Melnick A; Levine RL; Ferrando A; Mackerell AD; Kelleher NL; Licht JD; Popovic R
    Leukemia; 2014 Jan; 28(1):198-201. PubMed ID: 23823660
    [No Abstract]   [Full Text] [Related]  

  • 24. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
    Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
    Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The constitutional gain-of-function variant p.Glu1099Lys in NSD2 is associated with a novel syndrome.
    Popp B; Brugger M; Poschmann S; Bartolomaeus T; Radtke M; Hentschel J; Di Donato N; Rump A; Gburek-Augustat J; Graf E; Wagner M; Sorge I; Lemke JR; Meitinger T; Abou Jamra R; Strehlow V; Brunet T
    Clin Genet; 2023 Feb; 103(2):226-230. PubMed ID: 36189577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHSC1/NSD2 regulates immune infiltration in prostate cancer.
    Want MY; Tsuji T; Singh PK; Thorne JL; Matsuzaki J; Karasik E; Gillard B; Cortes Gomez E; Koya RC; Lugade A; Odunsi K; Battaglia S
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NSD2 as a Promising Target in Hematological Disorders.
    Azagra A; Cobaleda C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
    Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
    FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
    LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
    Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation and expression alterations of histone methylation-related NSD2, KDM2B and SETMAR genes in colon cancers.
    Moon SW; Son HJ; Mo HY; Choi EJ; Yoo NJ; Lee SH
    Pathol Res Pract; 2021 Mar; 219():153354. PubMed ID: 33621919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
    Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
    Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
    Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
    PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NSD2 is downregulated in T2DM and promotes β cell proliferation and insulin secretion through the transcriptionally regulation of PDX1.
    Shi S; Zhao L; Zheng L
    Mol Med Rep; 2018 Sep; 18(3):3513-3520. PubMed ID: 30066931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal NSD2 Aggravates Nonalcoholic Steatohepatitis Through Histone Modifications.
    Zhang Y; Qiao Y; Li Z; Liu D; Jin Q; Guo J; Li X; Chen L; Liu L; Peng L
    Adv Sci (Weinh); 2024 Sep; 11(33):e2402551. PubMed ID: 38923875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
    Dilworth D; Hanley RP; Ferreira de Freitas R; Allali-Hassani A; Zhou M; Mehta N; Marunde MR; Ackloo S; Carvalho Machado RA; Khalili Yazdi A; Owens DDG; Vu V; Nie DY; Alqazzaz M; Marcon E; Li F; Chau I; Bolotokova A; Qin S; Lei M; Liu Y; Szewczyk MM; Dong A; Kazemzadeh S; Abramyan T; Popova IK; Hall NW; Meiners MJ; Cheek MA; Gibson E; Kireev D; Greenblatt JF; Keogh MC; Min J; Brown PJ; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; James LI; Schapira M
    Nat Chem Biol; 2022 Jan; 18(1):56-63. PubMed ID: 34782742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
    Wei J; Shi Q; Li B; Yang H; Liu L; Zhou R; Feng Z; Yang Z; Zhan J; Xiong XF; Huang X; Wang Y
    J Med Chem; 2024 Sep; 67(18):16056-16071. PubMed ID: 39230932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.